dan 2163 has been researched along with Chronic Disease in 15 studies
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "This multicenter, double-blind, randomized study evaluated the efficacy, safety and functional effects of two atypical antipsychotics, amisulpride and risperidone, in patients with chronic schizophrenia (DSM IV) with a recent worsening of symptoms." | 9.10 | Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. ( Fleurot, O; Lecrubier, Y; Peuskens, J; Rein, W; Sechter, D, 2002) |
| "Relapse was determined by assessing changes in Positive and Negative Syndrome Scale (PANSS) total scores from baseline to 6 months (increased over 20% or 10% reaching 70)." | 5.91 | Relapse in patients with schizophrenia and amisulpride-induced hyperprolactinemia or olanzapine-induced metabolic disturbance after switching to other antipsychotics. ( Cai, J; Gao, M; Huang, J; Huang, Y; Kang, D; Li, L; Liu, F; Long, Y; Ou, J; Peng, X; Shao, P; Shao, T; Shen, Y; Song, C; Su, Y; Sun, M; Wang, W; Wang, X; Wu, Q; Wu, R; Xiao, J; Xie, P; Yang, Y, 2023) |
| "This multicenter, double-blind, randomized study evaluated the efficacy, safety and functional effects of two atypical antipsychotics, amisulpride and risperidone, in patients with chronic schizophrenia (DSM IV) with a recent worsening of symptoms." | 5.10 | Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. ( Fleurot, O; Lecrubier, Y; Peuskens, J; Rein, W; Sechter, D, 2002) |
| " In this long-term, open, randomised, multicentre trial, patients with chronic or subchronic schizophrenia received amisulpride (n =370) or haloperidol (n = 118) for 12 months." | 5.09 | Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. ( Colonna, L; Dondey-Nouvel, L; Rein, W; Saleem, P, 2000) |
| " The drug had only a limited effect in reducing negative symptoms, which were relatively stable, enduring phenomena in this sample, despite dosage reduction." | 2.68 | One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol. ( Alberts, JL; Barnes, TR; Curson, DA; Pantelis, C; Speller, JC, 1997) |
| "22 patients (8 manic-depressive psychoses and 14 schizophrenias) were given sultopride as the sole therapy, in a daily dose of 4 vials." | 2.65 | [Longterm psychosis and sultopride]. ( Morel, D, 1983) |
| " Safety was monitored by open adverse event reporting, the Simpson-Angus Scale, the Barnes Akathisia Scale and the Abnormal Involuntary Movement scale." | 2.41 | Safety profile of amisulpride in short- and long-term use. ( Coulouvrat, C; Dondey-Nouvel, L; Rein, W, 2000) |
| " In patients with acute exacerbations of schizophrenia, the recommended dosage of amisulpride is 400 to 800 mg/day, although dosages < or =1200 mg/day may be administered." | 2.41 | Amisulpride: a review of its use in the management of schizophrenia. ( Curran, MP; Perry, CM, 2001) |
| "Relapse was determined by assessing changes in Positive and Negative Syndrome Scale (PANSS) total scores from baseline to 6 months (increased over 20% or 10% reaching 70)." | 1.91 | Relapse in patients with schizophrenia and amisulpride-induced hyperprolactinemia or olanzapine-induced metabolic disturbance after switching to other antipsychotics. ( Cai, J; Gao, M; Huang, J; Huang, Y; Kang, D; Li, L; Liu, F; Long, Y; Ou, J; Peng, X; Shao, P; Shao, T; Shen, Y; Song, C; Su, Y; Sun, M; Wang, W; Wang, X; Wu, Q; Wu, R; Xiao, J; Xie, P; Yang, Y, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (13.33) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 9 (60.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, J | 1 |
| Li, L | 1 |
| Shao, T | 1 |
| Sun, M | 1 |
| Wang, W | 1 |
| Xie, P | 1 |
| Wang, X | 1 |
| Yang, Y | 1 |
| Long, Y | 1 |
| Kang, D | 1 |
| Xiao, J | 1 |
| Su, Y | 1 |
| Peng, X | 1 |
| Huang, Y | 1 |
| Gao, M | 1 |
| Wu, Q | 1 |
| Song, C | 1 |
| Liu, F | 1 |
| Shao, P | 1 |
| Ou, J | 1 |
| Shen, Y | 1 |
| Huang, J | 1 |
| Wu, R | 1 |
| Mendhekar, DN | 1 |
| Sechter, D | 1 |
| Peuskens, J | 1 |
| Fleurot, O | 1 |
| Rein, W | 3 |
| Lecrubier, Y | 2 |
| French, K | 1 |
| Eastwood, D | 1 |
| Quintin, P | 1 |
| Bouhassira, M | 1 |
| Perrin, E | 1 |
| Lancrenon, S | 1 |
| Morel, D | 1 |
| Miyachi, Y | 1 |
| Mizuchi, A | 1 |
| Hamano, H | 1 |
| Sarai, K | 1 |
| Freeman, HL | 1 |
| Speller, JC | 1 |
| Barnes, TR | 1 |
| Curson, DA | 1 |
| Pantelis, C | 1 |
| Alberts, JL | 1 |
| Möller, HJ | 2 |
| Coulouvrat, C | 1 |
| Dondey-Nouvel, L | 2 |
| Colonna, L | 1 |
| Saleem, P | 1 |
| Curran, MP | 1 |
| Perry, CM | 1 |
4 reviews available for dan 2163 and Chronic Disease
| Article | Year |
|---|---|
Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: three efficacy studies.
Topics: Adult; Amisulpride; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Double- | 1997 |
Amisulpride: a review of its efficacy in schizophrenia.
Topics: Acute Disease; Amisulpride; Antipsychotic Agents; Brief Psychiatric Rating Scale; Chronic Disease; C | 2000 |
Safety profile of amisulpride in short- and long-term use.
Topics: Amisulpride; Antipsychotic Agents; Chronic Disease; Clinical Trials as Topic; Drug Administration Sc | 2000 |
Amisulpride: a review of its use in the management of schizophrenia.
Topics: Acute Disease; Administration, Oral; Adsorption; Amisulpride; Antipsychotic Agents; Chronic Disease; | 2001 |
6 trials available for dan 2163 and Chronic Disease
| Article | Year |
|---|---|
Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study.
Topics: Adolescent; Adult; Aged; Amisulpride; Analysis of Variance; Chi-Square Distribution; Chronic Disease | 2002 |
The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial.
Topics: Adult; Affect; Amisulpride; Antipsychotic Agents; Attention; Basal Ganglia Diseases; Benzodiazepines | 2006 |
[Longterm psychosis and sultopride].
Topics: Adult; Amisulpride; Chronic Disease; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Ps | 1983 |
One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol.
Topics: Adult; Aged; Amisulpride; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Female; Humans | 1997 |
Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group.
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Chronic Disease; Dyskinesia, Drug-Induce | 2000 |
Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms of schizophrenia.
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; | 2001 |
5 other studies available for dan 2163 and Chronic Disease
| Article | Year |
|---|---|
Relapse in patients with schizophrenia and amisulpride-induced hyperprolactinemia or olanzapine-induced metabolic disturbance after switching to other antipsychotics.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chronic Disease; Humans; Hyperprol | 2023 |
Hyperpigmentation with amisulpride.
Topics: Adult; Amisulpride; Antipsychotic Agents; Chronic Disease; Drug Therapy, Combination; Female; Fluvox | 2009 |
Response of catatonic schizophrenia to amisulpride: a case report.
Topics: Adult; Amisulpride; Antipsychotic Agents; Chronic Disease; Humans; Male; Schizophrenia, Catatonic; S | 2003 |
Effects of chronic sultopride treatment on endocrine systems in psychotic women.
Topics: Adult; Amisulpride; Chronic Disease; Estradiol; Female; Follicle Stimulating Hormone; Growth Hormone | 1984 |
[Amisulpride--a neuroleptic agent for all phases of schizophrenia].
Topics: Amisulpride; Antipsychotic Agents; Chronic Disease; Humans; Hyperkinesis; Hypertension; Risk Factors | 1999 |